Overview

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-04-10

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety and tolerability of RC48-ADC with JS001 compared with RC48-ADC in endocrine-resistant hormone receptor (HR) positive, human epidermal growth factor receptor (HER)2-low advanced breast cancer.

Phase:

Phase 2

Details

Lead Sponsor:

RemeGen Co., Ltd.

Treatments:

Disitamab vedotin